USPTO serial 79433974
NORDICCTX-III
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- SEVERSON, JUSTIN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with NORDICCTX-III?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic biomarker reagents for medical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; diagnostic biomarker assays to identify disease activity for medical use; diagnostic biomarker assays for medical use to quantify disease activity; diagnostic biomarker assays for medical use to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for testing bodily fluids for use in disease detection, disease analysis and quantifying disease activity; diagnostic agents for medical use; diagnostic reagents for medical use; clinical diagnostic agents; clinical diagnostic reagents for medical use; diagnostic preparations, diagnostic substances and diagnostic materials for medical purposes; medical diagnostic test strips for testing samples for the presence of biomarkers; diagnostic preparations for medical purposes | ACTIVE | — |
| 042 | Design and development of blood-based biomarker assays for the identification, quantification and analysis of disease activity; design and development of diagnostic biomarker reagents for medical purposes, for pharmaceutical purposes and for scientific purposes; design and development of biochemical and pharmaceutical assays and medical assays; design and development of biomarkers for individual use or combined for the tracking of tissue formation, development or tissue degradation; pharmaceutical and scientific research in the fields of biomarkers and the detection of biomarkers; medical research, namely, identification of predictive and prognostic biomarkers for clinical trials; medical research, namely, identifying patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; scientific research in the nature of conducting clinical trials for others; medical research, namely, analysis of pharmacodynamic data; medical research, namely, analysis of data relating to biomarkers; development of diagnostic preparations for medical purposes, diagnostic equipment and diagnostic tests; medical research laboratory services relating to clinical testing services for others; providing reagent sample testing and diagnostic services for others for scientific research purposes; medical research services, namely, testing services relating to the tracking and measurement of biomarkers; medical research services, namely, testing samples for the presence of biomarkers; scientific laboratory services; medical research laboratory services; medical research laboratories; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research services involving experimentation, development, and analysis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 27, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Aug 25, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 25, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 19, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 5, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 5, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jul 27, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 17, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 17, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 17, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 19, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 3, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 3, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 8, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 7, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 29, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 5, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 5, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 2, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |